<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002686</url>
  </required_header>
  <id_info>
    <org_study_id>Dragon VIII</org_study_id>
    <nct_id>NCT05002686</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis</brief_title>
  <official_title>Safety and Efficacy of Sintilimab in Combination With Albumin-Paclitaxel/Oxaliplatin/Capecitabine and Radiotherapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis: A Multiple Center Single Arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer with retroperitoneal lymph node metastasis was considered as unresectable, to&#xD;
      improve these patients' prognosis, we designed systematic conversion therapy including&#xD;
      immunotherapy and chemoradiotherapy. The purpose of this study is to estimate safety and&#xD;
      efficacy of Sintilimab in combination with chemoradiothrapy followed by D2 surgical resection&#xD;
      in patients with advanced gastric cancer with retroperitoneal lymph node metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 3 years after the first participant is included</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 surgical resection percentage</measure>
    <time_frame>Approximately 2 years after the first participant is included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative conversion percentage</measure>
    <time_frame>Approximately 2 years after the first participant is included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 4 years after the first participant is included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Approximately 4 years after the first participant is included</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pathologic complete response(pCR)</measure>
    <time_frame>Approximately 2 years after the first participant is included</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Potential biomarker to predict prognosis</measure>
    <time_frame>Approximately 4 years after the first participant is included</time_frame>
    <description>PD-L1 CPS, EBV expression, Tumor Mutational Burden(TMB), MSI-H/dMMR</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200 mg Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin-Paclitaxel</intervention_name>
    <description>200 mg/m^2 Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 Q3W on Day 1 by IV infusion</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy*25.</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical gastric cancer surgery</intervention_name>
    <description>Radical gastric cancer surgery with D2 lymph node dissection</description>
    <arm_group_label>Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathology confirmed Gastric/Gastricgastroesophageal junction adenocarcinoma;&#xD;
&#xD;
          -  Radiolgical imging including CT,PET-CT or MRI diagnosed as retroperitoneal metastasis.&#xD;
&#xD;
          -  Did not receive previous systemic treatment (chemotheray, radiotherapy or both) for&#xD;
             advanced disease before.&#xD;
&#xD;
          -  ECOG PS 0-2.&#xD;
&#xD;
          -  Adequate organ and bone marrow functions and life expectancy ≥12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases except retroperitoneal metastasis (liver, lung, peitoneal&#xD;
             metastasis...);&#xD;
&#xD;
          -  HER2-positive status;&#xD;
&#xD;
          -  Suspicious active bleeding or gastriointestineal obstruction phenomenon and Has&#xD;
             difficulty in swallow tablets and food;&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD&#xD;
             L2 , anti-CD137,anti-CTLA-4 agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Is currently participating in and receiving study therapy ,except those in the&#xD;
             survival follow up period of an investigational agent study or non-interventional&#xD;
             study .&#xD;
&#xD;
          -  Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)&#xD;
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or&#xD;
             topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic&#xD;
             reaction of i.v. contrast agent are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Known acute or chronic active hepatitis B infection (positive HBsAg and HBV DNA ≥ 200&#xD;
             IU/mL or ≥ 10^3 copies/mL positive) infection or acute or chronic active hepatitis C&#xD;
             (HCV antibody positive and HCV RNA positive) infection.&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan&#xD;
             to receive live vaccine during study period.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease or has a history of the disease within&#xD;
             the last 2 years (subjects with vitiligo, psoriasis, alopecia or Grave's disease,&#xD;
             residual hypothyroidism due to autoimmune thyroiditis only requiring hormone&#xD;
             replacement, or type I diabetes mellitus only requiring insulin replacement, but not&#xD;
             required systemic treatment in the last 2 years, are permitted to enroll) .&#xD;
&#xD;
          -  Known primary immunodeficiency.&#xD;
&#xD;
          -  Known active tuberculosis.&#xD;
&#xD;
          -  Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation.&#xD;
&#xD;
          -  Known&gt;=grade 3 allergy or hypersensitivity to Albumin-paclitaxel oxaliplatin,&#xD;
             capecitabine or any monoclonal antibodies.&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV) infection (HIV antibody positive).&#xD;
&#xD;
          -  Poorly controlled arterial hypertension (SBP ≥ 160mmHg or DBP ≥ 100 mmHg) with&#xD;
             standard treatment .&#xD;
&#xD;
          -  Symptomatic congestive heart failure (New York Heart Association grade II-IV) or&#xD;
             symptomatic, poorly controlled arrhythmia.&#xD;
&#xD;
          -  Prior arterial thromboembolism event, including myocardial infarction, unstable&#xD;
             angina, stroke and transient ischemic attack, within 6 months of enrollment.&#xD;
&#xD;
          -  Active or poorly controlled severe infection.&#xD;
&#xD;
          -  History of gastrointestinal perforation and /or fistula within 6 months before&#xD;
             enrollment.&#xD;
&#xD;
          -  Other acute or chronic diseases, mental illness, or abnormal laboratory test results&#xD;
             that may lead to the following outcomes: increase the risk of participating in study&#xD;
             or study drug administration, or interfere with the interpretation of the study&#xD;
             results and considered by investigator as &quot;NOT&quot; eligible to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin hospital affiliatted to Shanghai Jiaotong University school of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changyu He, PhD</last_name>
    <phone>8618817821339</phone>
    <email>hechangyu.2008@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Li, PhD, MD</last_name>
      <phone>8602164370045</phone>
      <email>leedoctor@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Chen Li</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>retroperitoneal lymph node metastasis</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>surgical resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

